Mark J. Mitton‐Fry

Oclacitinib (<scp>APOQUEL</scp>^®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy

Andrea J. Gonzales, Jill Bowman, Gregory J. Fici et al. · Journal of Veterinary Pharmacology and Therapeutics · 2014 · 236 citations · Full text

Identification of <i>N</i>-{<i>cis</i>-3-[Methyl(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases

Michael L. Vazquez, Neelu Kaila, Joseph W. Strohbach et al. · Journal of Medicinal Chemistry · 2018 · 160 citations · Full text

Immunodeficiencies, Janus Kinases, Immunology +22

Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis

Robert S. Wallis, Wesley Jakubiec, Vikas Kumar et al. · Antimicrobial Agents and Chemotherapy · 2010 · 126 citations · Full text

Early Development, Tuberculosis Prevention, Pharmacotherapy +18

Pharmacokinetics and Whole‐Blood Bactericidal Activity against<i>Mycobacterium tuberculosis</i>of Single Doses of PNU‐100480 in Healthy Volunteers

Robert S. Wallis, Wesley Jakubiec, Vikas Kumar et al. · The Journal of Infectious Diseases · 2010 · 99 citations · Full text

Pyridone Methylsulfone Hydroxamate LpxC Inhibitors for the Treatment of Serious Gram-Negative Infections

Justin I. Montgomery, Matthew F. Brown, Usa Reilly et al. · Journal of Medicinal Chemistry · 2012 · 97 citations · Full text

Pharmaceutical Science, Pharmacotherapy, New Series +19